<?xml version="1.0" encoding="utf-8"?>
<rss 
  version="2.0">
  <channel xmlns:dc="http://dublincore.org/documents/dcmi-namespace/" xmlns:media="http://search.yahoo.com/mrss/">
    <title>Cellceutix Corporation</title>
    <link>https://www.globenewswire.com/rssfeed/organization/EHfI4uNtZpLwy8Y74YHjDQ==</link>
    <description>Contains the last 20 releases</description>
    <copyright>Copyright 2016, Cellceutix Corporation</copyright>
    <managingEditor>newsdesk@globenewswire.com (NewsDesk)</managingEditor>
    <lastBuildDate>Fri, 16 Sep 2016 15:00:00 GMT</lastBuildDate>
    <webMaster>webmaster@globenewswire.com (Webmaster)</webMaster>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2016/09/16/955512/0/en/Cellceutix-Announces-Appointment-of-Vice-President-for-Regulatory-Affairs.html</guid>
      <link>https://www.globenewswire.com/news-release/2016/09/16/955512/0/en/Cellceutix-Announces-Appointment-of-Vice-President-for-Regulatory-Affairs.html</link>
      <title>Cellceutix Announces Appointment of Vice President for Regulatory Affairs</title>
      <description><![CDATA[<p><span class="mw_region">BEVERLY, MA</span><span>--(Marketwired - September 16, 2016) - </span>Cellceutix Corporation, (<exchange name="OTC">OTC</exchange>: <ticker name="CTIX">CTIX</ticker>) ("the Company"), a clinical stage biopharmaceutical company developing innovative therapies with dermatology, oncology, antibiotic, and anti-inflammatory applications, is pleased to announce today the appointment of LaVonne Lang, DrPH, to the role of Vice President, Regulatory Affairs. </p>]]></description>
      <pubDate>Fri, 16 Sep 2016 15:00 GMT</pubDate>
      <dc:identifier>955512</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Cellceutix</dc:contributor>
      <dc:modified>Wed, 20 Sep 2017 01:36 GMT</dc:modified>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2016/09/13/955511/0/en/Cellceutix-Corporation-Provides-Business-Update-and-Timeline-of-Upcoming-Milestones.html</guid>
      <link>https://www.globenewswire.com/news-release/2016/09/13/955511/0/en/Cellceutix-Corporation-Provides-Business-Update-and-Timeline-of-Upcoming-Milestones.html</link>
      <title>Cellceutix Corporation Provides Business Update and Timeline of Upcoming Milestones</title>
      <description><![CDATA[<p><span class="mw_region">BEVERLY, MA</span><span>--(Marketwired - September 13, 2016) - </span> Cellceutix Corporation (<exchange name="OTC">OTC</exchange>: <ticker name="CTIX">CTIX</ticker>) ("the Company"), a clinical stage biopharmaceutical company developing innovative therapies with dermatology, oncology, antibiotic, and anti-inflammatory applications, today provided a fiscal year-end business update including a timeline of key upcoming milestones.</p>]]></description>
      <pubDate>Tue, 13 Sep 2016 12:30 GMT</pubDate>
      <dc:identifier>955511</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Cellceutix</dc:contributor>
      <dc:modified>Wed, 20 Sep 2017 01:36 GMT</dc:modified>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2016/09/07/955510/0/en/Cellceutix-Corporation-to-Present-at-Upcoming-Conferences.html</guid>
      <link>https://www.globenewswire.com/news-release/2016/09/07/955510/0/en/Cellceutix-Corporation-to-Present-at-Upcoming-Conferences.html</link>
      <title>Cellceutix Corporation to Present at Upcoming Conferences</title>
      <description><![CDATA[<p><span class="mw_region">BEVERLY, MA</span><span>--(Marketwired - September 07, 2016) - </span>Cellceutix Corporation (<exchange name="OTC">OTC</exchange>: <ticker name="CTIX">CTIX</ticker>) ("the Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, antibiotic, and anti-inflammatory applications, today announces that management will present at two upcoming conferences highlighting the continuing advancement of the Company's clinical programs.</p>]]></description>
      <pubDate>Wed, 07 Sep 2016 11:00 GMT</pubDate>
      <dc:identifier>955510</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Cellceutix</dc:contributor>
      <dc:modified>Wed, 20 Sep 2017 01:36 GMT</dc:modified>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2016/08/30/955509/0/en/Cellceutix-Further-Expands-Its-Senior-Management-Team-With-the-Addition-of-an-Industry-Veteran.html</guid>
      <link>https://www.globenewswire.com/news-release/2016/08/30/955509/0/en/Cellceutix-Further-Expands-Its-Senior-Management-Team-With-the-Addition-of-an-Industry-Veteran.html</link>
      <title>Cellceutix Further Expands Its Senior Management Team With the Addition of an Industry Veteran</title>
      <description><![CDATA[<p><span class="mw_region">BEVERLY, MA</span><span>--(Marketwired - August 30, 2016) - </span>Cellceutix Corporation (<exchange name="OTC">OTC</exchange>: <ticker name="CTIX">CTIX</ticker>) ("the Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, antibiotic, and anti-inflammatory applications, is pleased to announce today the addition of another senior executive to its management team. Jane Harness, MS, MP, has been appointed to the role of Vice President, Clinical Sciences and Portfolio Management. </p>]]></description>
      <pubDate>Tue, 30 Aug 2016 18:07 GMT</pubDate>
      <dc:identifier>955509</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Cellceutix</dc:contributor>
      <dc:modified>Wed, 20 Sep 2017 01:36 GMT</dc:modified>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2016/08/03/955508/0/en/Cellceutix-Prepares-Phase-2a-Ovarian-Cancer-Trial-of-Kevetrin-a-Novel-p53-Modulating-Drug-Candidate-Based-Upon-Phase-1-Topline-Data.html</guid>
      <link>https://www.globenewswire.com/news-release/2016/08/03/955508/0/en/Cellceutix-Prepares-Phase-2a-Ovarian-Cancer-Trial-of-Kevetrin-a-Novel-p53-Modulating-Drug-Candidate-Based-Upon-Phase-1-Topline-Data.html</link>
      <title>Cellceutix Prepares Phase 2a Ovarian Cancer Trial of Kevetrin, a Novel p53-Modulating Drug Candidate, Based Upon Phase 1 Topline Data</title>
      <description><![CDATA[<p><span class="mw_region">BEVERLY, MA</span><span>--(Marketwired - August 03, 2016) - </span>Cellceutix Corporation, (<exchange name="OTC">OTC</exchange>: <ticker name="CTIX">CTIX</ticker>) ("the Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, antibiotic, and anti-inflammatory applications, is pleased to provide topline data on the completed Phase 1 clinical trial of Kevetrin for the treatment of advanced solid tumors, which are among the hardest-to-treat types of cancers. </p>]]></description>
      <pubDate>Wed, 03 Aug 2016 13:30 GMT</pubDate>
      <dc:identifier>955508</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Cellceutix</dc:contributor>
      <dc:modified>Wed, 20 Sep 2017 01:36 GMT</dc:modified>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2016/07/21/955507/0/en/Cellceutix-Expedites-Phase-2-Trial-of-Brilacidin-OM-For-Oral-Mucositis.html</guid>
      <link>https://www.globenewswire.com/news-release/2016/07/21/955507/0/en/Cellceutix-Expedites-Phase-2-Trial-of-Brilacidin-OM-For-Oral-Mucositis.html</link>
      <title>Cellceutix Expedites Phase 2 Trial of Brilacidin-OM For Oral Mucositis</title>
      <description><![CDATA[<p><span class="mw_region">BEVERLY, MA </span><span>--(Marketwired - July 21, 2016) - </span>Cellceutix Corporation, (<exchange name="OTCQB">OTCQB</exchange>: <ticker name="CTIX">CTIX</ticker>) ("the Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, antibiotic, and anti-inflammatory applications, is pleased to provide additional information in the ongoing, Phase 2 clinical trial of Brilacidin-OM for the treatment of oral mucositis (OM), a serious and debilitating complication of radiation and chemotherapy for head and neck cancer.</p>]]></description>
      <pubDate>Thu, 21 Jul 2016 11:00 GMT</pubDate>
      <dc:identifier>955507</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Cellceutix</dc:contributor>
      <dc:modified>Wed, 20 Sep 2017 01:36 GMT</dc:modified>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2016/07/18/955506/0/en/Cellceutix-Receives-Update-on-First-Patient-Enrolled-in-Phase-2-Proof-of-Concept-Study-of-Brilacidin-for-Ulcerative-Proctitis.html</guid>
      <link>https://www.globenewswire.com/news-release/2016/07/18/955506/0/en/Cellceutix-Receives-Update-on-First-Patient-Enrolled-in-Phase-2-Proof-of-Concept-Study-of-Brilacidin-for-Ulcerative-Proctitis.html</link>
      <title>Cellceutix Receives Update on First Patient Enrolled in Phase 2 Proof-of-Concept Study of Brilacidin for Ulcerative Proctitis</title>
      <description><![CDATA[<p><em><p>Company Encouraged by Investigator Report of Significant Decrease in Symptoms in First Patient in One Week </p></em></p><p><span class="mw_region">BEVERLY, MA</span><span>--(Marketwired - July 18, 2016) - </span> Cellceutix Corporation, (<exchange name="OTCQB">OTCQB</exchange>: <ticker name="CTIX">CTIX</ticker>) ("the Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, antibiotic, and anti-inflammatory applications, is pleased to provide additional information in the ongoing, open-label Phase 2 Proof-of-Concept (P-o-C) trial of Brilacidin for the treatment of ulcerative proctitis (UP) or ulcerative proctosigmoiditis (UPS). Brilacidin is being evaluated in adults with active, mild to moderate UP or UPS present for at least three months prior to screening with disease extending at least five centimeters, but no further than 40 centimeters from the anal verge, as confirmed by sigmoidoscopic examination.</p>]]></description>
      <pubDate>Mon, 18 Jul 2016 14:00 GMT</pubDate>
      <dc:identifier>955506</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Cellceutix</dc:contributor>
      <dc:modified>Wed, 20 Sep 2017 01:36 GMT</dc:modified>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2016/07/07/955505/0/en/Cellceutix-to-Initiate-Phase-2b-Trial-of-Prurisol-for-Chronic-Plaque-Psoriasis.html</guid>
      <link>https://www.globenewswire.com/news-release/2016/07/07/955505/0/en/Cellceutix-to-Initiate-Phase-2b-Trial-of-Prurisol-for-Chronic-Plaque-Psoriasis.html</link>
      <title>Cellceutix to Initiate Phase 2b Trial of Prurisol for Chronic Plaque Psoriasis</title>
      <description><![CDATA[<p><span class="mw_region">BEVERLY, MA</span><span>--(Marketwired - July 07, 2016) - </span> Cellceutix Corporation, (<exchange name="OTC">OTC</exchange>: <ticker name="CTIX">CTIX</ticker>) ("the Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, antibiotic, and anti-inflammatory applications, is pleased to provide shareholders information on the next phases of clinical and corporate development following the recent appointment of Arthur P. Bertolino, MD, PhD, MBA as President and Chief Medical Officer.</p>]]></description>
      <pubDate>Thu, 07 Jul 2016 12:30 GMT</pubDate>
      <dc:identifier>955505</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Cellceutix</dc:contributor>
      <dc:modified>Wed, 20 Sep 2017 01:36 GMT</dc:modified>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2016/06/30/955504/0/en/Cellceutix-Corporation-Announces-Industry-Veteran-Arthur-P-Bertolino-MD-PhD-MBA-Joins-Company-as-President-and-Chief-Medical-Officer.html</guid>
      <link>https://www.globenewswire.com/news-release/2016/06/30/955504/0/en/Cellceutix-Corporation-Announces-Industry-Veteran-Arthur-P-Bertolino-MD-PhD-MBA-Joins-Company-as-President-and-Chief-Medical-Officer.html</link>
      <title>Cellceutix Corporation Announces Industry Veteran Arthur P. Bertolino, MD, PhD, MBA Joins Company as President and Chief Medical Officer</title>
      <description><![CDATA[<p><span class="mw_region">BEVERLY, MA</span><span>--(Marketwired - June 30, 2016) - </span> Cellceutix Corporation, (<exchange name="OTC">OTC</exchange>: <ticker name="CTIX">CTIX</ticker>) ("the Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, antibiotic, and anti-inflammatory applications, today announces the appointment of Arthur P. Bertolino, MD, PhD, MBA, as President and Chief Medical Officer. Dr. Krishna Menon will continue to serve as Chief Scientific Officer and President of Research at Cellceutix. Dr. Bertolino is a leading pharmaceutical executive with over fifteen years of domestic and international drug development and management experience. Dr. Bertolino's responsibilities will include, but are not limited to, day-to-day operations for all aspects of the Company, including pipeline development, cohesion of clinical and business strategies, team building and exploration of partnering opportunities. </p>]]></description>
      <pubDate>Thu, 30 Jun 2016 17:00 GMT</pubDate>
      <dc:identifier>955504</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Cellceutix</dc:contributor>
      <dc:modified>Wed, 20 Sep 2017 01:36 GMT</dc:modified>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2016/06/15/955503/0/en/Cellceutix-Starts-Phase-2-Trial-of-Brilacidin-as-a-Novel-Therapy-for-Ulcerative-Proctitis.html</guid>
      <link>https://www.globenewswire.com/news-release/2016/06/15/955503/0/en/Cellceutix-Starts-Phase-2-Trial-of-Brilacidin-as-a-Novel-Therapy-for-Ulcerative-Proctitis.html</link>
      <title>Cellceutix Starts Phase 2 Trial of Brilacidin as a Novel Therapy for Ulcerative Proctitis</title>
      <description><![CDATA[<p><span class="mw_region">BEVERLY, MA</span><span>--(Marketwired - June 15, 2016) - </span>Cellceutix Corporation (<exchange name="OTC">OTC</exchange>: <ticker name="CTIX">CTIX</ticker>) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, antibiotic, and anti-inflammatory applications, today announces that patients have been screened and the administration of Brilacidin to patients is expected to begin this week in the Phase 2 Proof of Concept trial of Brilacidin for the treatment of ulcerative proctitis. </p>]]></description>
      <pubDate>Wed, 15 Jun 2016 15:45 GMT</pubDate>
      <dc:identifier>955503</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Cellceutix</dc:contributor>
      <dc:modified>Wed, 20 Sep 2017 01:36 GMT</dc:modified>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2016/06/09/955502/0/en/Cellceutix-Announces-Dismissal-of-Class-Action-Lawsuit-Filed-by-Rosen-Law-Firm.html</guid>
      <link>https://www.globenewswire.com/news-release/2016/06/09/955502/0/en/Cellceutix-Announces-Dismissal-of-Class-Action-Lawsuit-Filed-by-Rosen-Law-Firm.html</link>
      <title>Cellceutix Announces Dismissal of Class Action Lawsuit Filed by Rosen Law Firm</title>
      <description><![CDATA[<p><span class="mw_region">BEVERLY, MA</span><span>--(Marketwired - June 09, 2016) - </span>Cellceutix Corporation (<exchange name="OTC">OTC</exchange>: <ticker name="CTIX">CTIX</ticker>) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to announce that, yesterday, the U.S. District Court for the Southern District of New York granted the Company's motion to dismiss the securities class action lawsuit brought against the Company by a plaintiff represented by the Rosen Law Firm. </p>]]></description>
      <pubDate>Thu, 09 Jun 2016 14:50 GMT</pubDate>
      <dc:identifier>955502</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Cellceutix</dc:contributor>
      <dc:modified>Wed, 20 Sep 2017 01:36 GMT</dc:modified>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2016/06/06/955501/0/en/Cellceutix-Announces-Database-Lock-in-Phase-1-Trial-of-Kevetrin-a-Promising-New-Cancer-Treatment-That-Activates-p53.html</guid>
      <link>https://www.globenewswire.com/news-release/2016/06/06/955501/0/en/Cellceutix-Announces-Database-Lock-in-Phase-1-Trial-of-Kevetrin-a-Promising-New-Cancer-Treatment-That-Activates-p53.html</link>
      <title>Cellceutix Announces Database Lock in Phase 1 Trial of Kevetrin, a Promising New Cancer Treatment That Activates p53</title>
      <description><![CDATA[<p><span class="mw_region">BEVERLY, MA</span><span>--(Marketwired - June 06, 2016) - </span>Cellceutix Corporation (<exchange name="OTC">OTC</exchange>: <ticker name="CTIX">CTIX</ticker>) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, antibiotic, and anti-inflammatory applications, is pleased to announce that the study database from the Phase 1 trial of Kevetrin (thioureidobutyronitrile) for advanced solid tumors will be "soft locked" this week. These locked results are the final protocol requirement for the study of Kevetrin in its next clinical trial and will be added to the already prepared documentation for submission to the U.S. Food and Drug Administration ("FDA") in support of the planned Phase 1b/2 trial of Kevetrin in ovarian cancer patients with resistance to platinum-based therapies. Cellceutix is developing Kevetrin under an Orphan Drug designation from the FDA.</p>]]></description>
      <pubDate>Mon, 06 Jun 2016 11:00 GMT</pubDate>
      <dc:identifier>955501</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Cellceutix</dc:contributor>
      <dc:modified>Wed, 20 Sep 2017 01:36 GMT</dc:modified>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2016/05/31/955500/0/en/Cellceutix-Releases-Pharmacokinetics-Data-From-Phase-2-Trial-of-Prurisol-for-Treating-Psoriasis-Data-Complements-Efficacy-Data-Reported-Last-Week.html</guid>
      <link>https://www.globenewswire.com/news-release/2016/05/31/955500/0/en/Cellceutix-Releases-Pharmacokinetics-Data-From-Phase-2-Trial-of-Prurisol-for-Treating-Psoriasis-Data-Complements-Efficacy-Data-Reported-Last-Week.html</link>
      <title>Cellceutix Releases Pharmacokinetics Data From Phase 2 Trial of Prurisol for Treating Psoriasis; Data Complements Efficacy Data Reported Last Week</title>
      <description><![CDATA[<p>
    <span class="mw_region">BEVERLY, MA</span><span>--(Marketwired - May 31, 2016) - </span> Cellceutix Corporation (<exchange name="OTC">OTC</exchange>: <ticker name="CTIX">CTIX</ticker>) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, antibiotic, and anti-inflammatory applications, is pleased to announce that the pharmacokinetics (PK) data on the recently completed Phase 2 trial of Prurisol as a novel oral treatment for plaque psoriasis has been received and is starting to be analyzed.</p>]]></description>
      <pubDate>Tue, 31 May 2016 11:00 GMT</pubDate>
      <dc:identifier>955500</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Cellceutix</dc:contributor>
      <dc:modified>Wed, 20 Sep 2017 01:36 GMT</dc:modified>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2016/05/26/955499/0/en/Cellceutix-Provides-Additional-Insight-Into-Successful-Phase-2-Trial-for-Treating-Psoriasis.html</guid>
      <link>https://www.globenewswire.com/news-release/2016/05/26/955499/0/en/Cellceutix-Provides-Additional-Insight-Into-Successful-Phase-2-Trial-for-Treating-Psoriasis.html</link>
      <title>Cellceutix Provides Additional Insight Into Successful Phase 2 Trial for Treating Psoriasis</title>
      <description><![CDATA[<p>
    <span class="mw_region">BEVERLY, MA</span><span>--(Marketwired - May 26, 2016) - </span> Cellceutix Corporation (<exchange name="OTC">OTC</exchange>: <ticker name="CTIX">CTIX</ticker>) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, antibiotic, and anti-inflammatory applications, today provides additional insight into the successfully completed Phase 2 trial of Prurisol as a new oral therapy for mild to moderate plaque psoriasis.</p>]]></description>
      <pubDate>Thu, 26 May 2016 11:00 GMT</pubDate>
      <dc:identifier>955499</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Cellceutix</dc:contributor>
      <dc:modified>Wed, 20 Sep 2017 01:36 GMT</dc:modified>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2016/05/24/955498/0/en/Cellceutix-Phase-2-Trial-of-Prurisol-for-Mild-to-Moderate-Psoriasis-Meets-Primary-Endpoint.html</guid>
      <link>https://www.globenewswire.com/news-release/2016/05/24/955498/0/en/Cellceutix-Phase-2-Trial-of-Prurisol-for-Mild-to-Moderate-Psoriasis-Meets-Primary-Endpoint.html</link>
      <title>Cellceutix Phase 2 Trial of Prurisol for Mild to Moderate Psoriasis Meets Primary Endpoint</title>
      <description><![CDATA[<p>
    <span class="mw_region">BEVERLY, MA</span><span>--(Marketwired - May 24, 2016) - </span>
  </p>]]></description>
      <pubDate>Tue, 24 May 2016 14:00 GMT</pubDate>
      <dc:identifier>955498</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Cellceutix</dc:contributor>
      <dc:modified>Wed, 20 Sep 2017 01:36 GMT</dc:modified>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2016/05/11/955497/0/en/Data-From-Phase-2-Trial-of-Prurisol-for-Psoriasis-to-Be-Unblinded-Next-Week-Top-Line-Results-to-Follow.html</guid>
      <link>https://www.globenewswire.com/news-release/2016/05/11/955497/0/en/Data-From-Phase-2-Trial-of-Prurisol-for-Psoriasis-to-Be-Unblinded-Next-Week-Top-Line-Results-to-Follow.html</link>
      <title>Data From Phase 2 Trial of Prurisol for Psoriasis to Be Unblinded Next Week, Top-Line Results to Follow</title>
      <description><![CDATA[<p>
    <span class="mw_region">BEVERLY, MA</span><span>--(Marketwired - May 11, 2016) - </span> Cellceutix Corporation (<exchange name="OTC">OTC</exchange>: <ticker name="CTIX">CTIX</ticker>) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to announce that the clinical database for the Phase 2 clinical trial of Prurisol for the treatment of mild-to-moderate chronic plaque psoriasis is expected to be "unblinded" next week. Once the blind is removed, data from each of the four arms of the trial (one placebo arm, three oral dosing regimens of Prurisol) will be reviewed and analyzed to evaluate the safety and efficacy of Prurisol. Cellceutix expects to release top-line data from the study approximately one week after the blind is removed.</p>]]></description>
      <pubDate>Wed, 11 May 2016 13:30 GMT</pubDate>
      <dc:identifier>955497</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Cellceutix</dc:contributor>
      <dc:modified>Wed, 20 Sep 2017 01:36 GMT</dc:modified>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2016/04/19/955496/0/en/Cellceutix-Institutes-Database-Soft-Lock-on-Its-Phase-2-Psoriasis-Clinical-Trial-Top-Line-Results-Anticipated-in-May-Additional-Company-Updates.html</guid>
      <link>https://www.globenewswire.com/news-release/2016/04/19/955496/0/en/Cellceutix-Institutes-Database-Soft-Lock-on-Its-Phase-2-Psoriasis-Clinical-Trial-Top-Line-Results-Anticipated-in-May-Additional-Company-Updates.html</link>
      <title>Cellceutix Institutes "Database Soft Lock" on Its Phase 2 Psoriasis Clinical Trial, Top Line Results Anticipated in May; Additional Company Updates</title>
      <description><![CDATA[<p>
    <span class="mw_region">BEVERLY, MA</span><span>--(Marketwired - April 19, 2016) - </span> Cellceutix Corporation (<exchange name="OTC">OTC</exchange>: <ticker name="CTIX">CTIX</ticker>) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to inform shareholders that the clinical database for Prurisol's Phase 2 FDA trial for mild-to-moderate chronic plaque psoriasis has instituted a "Database Soft Lock."</p>]]></description>
      <pubDate>Tue, 19 Apr 2016 14:30 GMT</pubDate>
      <dc:identifier>955496</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Cellceutix</dc:contributor>
      <dc:modified>Wed, 20 Sep 2017 01:36 GMT</dc:modified>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2016/03/31/955495/0/en/Cellceutix-Successfully-Completes-In-Vitro-Study-in-Support-of-Planned-Phase-2-Trial-of-Kevetrin-for-Ovarian-Cancer.html</guid>
      <link>https://www.globenewswire.com/news-release/2016/03/31/955495/0/en/Cellceutix-Successfully-Completes-In-Vitro-Study-in-Support-of-Planned-Phase-2-Trial-of-Kevetrin-for-Ovarian-Cancer.html</link>
      <title>Cellceutix Successfully Completes In Vitro Study in Support of Planned Phase 2 Trial of Kevetrin for Ovarian Cancer</title>
      <description><![CDATA[<p><em><p>Research on CYP450 Shows No Concerns for Adverse Drug-Drug Interactions in Combination Therapy </p></em></p><p>
    <span class="mw_region">BEVERLY, MA</span><span>--(Marketwired - March 31, 2016) - </span>Cellceutix Corporation (<exchange name="OTC">OTC</exchange>: <ticker name="CTIX">CTIX</ticker>) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to announce that the latest laboratory research on the Company's anti-cancer drug Kevetrin showed that Kevetrin did not inhibit or induce cytochrome P450 enzymes in vitro. Based upon the documented relationship of P450 and certain potential drug-drug interactions, this positive data is central to the planned Phase 2 clinical trial where Kevetrin will be used in a combination therapy for the treatment of ovarian cancer.</p>]]></description>
      <pubDate>Thu, 31 Mar 2016 13:00 GMT</pubDate>
      <dc:identifier>955495</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Cellceutix</dc:contributor>
      <dc:modified>Wed, 20 Sep 2017 01:36 GMT</dc:modified>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2016/03/30/955494/0/en/Cellceutix-Receives-Preliminary-Approval-for-Clinical-Trial-of-Brilacidin-for-Ulcerative-Proctitis.html</guid>
      <link>https://www.globenewswire.com/news-release/2016/03/30/955494/0/en/Cellceutix-Receives-Preliminary-Approval-for-Clinical-Trial-of-Brilacidin-for-Ulcerative-Proctitis.html</link>
      <title>Cellceutix Receives Preliminary Approval for Clinical Trial of Brilacidin for Ulcerative Proctitis</title>
      <description><![CDATA[<p>
    <span class="mw_region">BEVERLY, MA</span><span>--(Marketwired - March 30, 2016) - </span>Cellceutix Corporation (<exchange name="OTC">OTC</exchange>: <ticker name="CTIX">CTIX</ticker>) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to announce that the Company has received initial approval for the planned Proof of Concept, Phase 2, clinical trial of Brilacidin for ulcerative proctitis. </p>]]></description>
      <pubDate>Wed, 30 Mar 2016 14:00 GMT</pubDate>
      <dc:identifier>955494</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Cellceutix</dc:contributor>
      <dc:modified>Wed, 20 Sep 2017 01:36 GMT</dc:modified>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2016/03/17/955493/0/en/Cellceutix-Concludes-Last-Patient-Visit-in-Phase-2-FDA-Trial-of-Oral-Dosed-Prurisol-in-Patients-With-Mild-to-Moderate-Chronic-Plaque-Psoriasis.html</guid>
      <link>https://www.globenewswire.com/news-release/2016/03/17/955493/0/en/Cellceutix-Concludes-Last-Patient-Visit-in-Phase-2-FDA-Trial-of-Oral-Dosed-Prurisol-in-Patients-With-Mild-to-Moderate-Chronic-Plaque-Psoriasis.html</link>
      <title>Cellceutix Concludes Last Patient Visit in Phase 2 FDA Trial of Oral Dosed Prurisol in Patients With Mild-to-Moderate Chronic Plaque Psoriasis</title>
      <description><![CDATA[<p>
    <span class="mw_region">BEVERLY, MA</span><span>--(Marketwired - March 17, 2016) - </span> Cellceutix (<exchange name="OTC">OTC</exchange>: <ticker name="CTIX">CTIX</ticker>) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to announce the conclusion of the last patient visit in its randomized, double-blind Phase 2 trial of orally-administered Prurisol for the treatment of mild to moderate chronic plaque psoriasis. The unblinding of the study and top-line data is expected to be available in May. Although the data is still blinded, there were no safety items of concern.</p>]]></description>
      <pubDate>Thu, 17 Mar 2016 14:00 GMT</pubDate>
      <dc:identifier>955493</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Cellceutix</dc:contributor>
      <dc:modified>Wed, 20 Sep 2017 01:36 GMT</dc:modified>
    </item>
  </channel>
</rss>